Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
Abstract Despite recent advancements in the treatment of multiple myeloma (MM), nearly all patients ultimately relapse and many become refractory to multiple lines of therapies. Therefore, we not only need the ability to predict which patients are at high risk for disease progression but also a mean...
Guardado en:
Autores principales: | Matthew A. Wall, Serdar Turkarslan, Wei-Ju Wu, Samuel A. Danziger, David J. Reiss, Mike J. Mason, Andrew P. Dervan, Matthew W. B. Trotter, Douglas Bassett, Robert M. Hershberg, Adrián López García de Lomana, Alexander V. Ratushny, Nitin S. Baliga |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8be0e48133514e37800ac2c098080257 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Accelerated single cell seeding in relapsed multiple myeloma
por: Heather J. Landau, et al.
Publicado: (2020) -
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Mary H. Young, et al.
Publicado: (2021) -
Selective Translation of Low Abundance and Upregulated Transcripts in <named-content content-type="genus-species">Halobacterium salinarum</named-content>
por: Adrián López García de Lomana, et al.
Publicado: (2020) -
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013) -
Author Correction: Accelerated single cell seeding in relapsed multiple myeloma
por: Heather J. Landau, et al.
Publicado: (2021)